Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Code Biotherapeutics
Biotech
Takeda trims early-stage efforts in AAV gene therapy, hematology
Takeda is moving away from early R&D work in AAV gene therapy and rare hematology, with an unknown number of employees set to “transition out."
Gabrielle Masson
Apr 6, 2023 4:08pm
Past and present GSK execs take on new roles—Chutes & Ladders
Nov 18, 2022 9:30am
Moderna promotes Andres to new strategy role—Chutes & Ladders
Sep 30, 2022 9:30am
Takeda's path to deCode rare diseases: A $2B gene therapy pact
Feb 22, 2022 10:15am
